1.400USD+1.45%Mkt Cap: 100.86M USDP/E: —Last update: 2026-06-01
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidat…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap100.86M USD
Enterprise Value56.32M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-61.80M USD
Revenue/Share—
Last Price1.400 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees41
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.25
PEG—
EV/EBITDA-0.89
EV/Revenue—
P/S—
P/B5.33
EPS (TTM)-0.55
EPS (Forward)-1.10
52W Range
0.872024% of range3.080
52W High3.080 USD
52W Low0.8720 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-209.11%
ROA-105.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-70.37M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-32.58%
Net Debt-43.45M USD
Net Debt/EBITDA0.69
Balance Sheet
Debt/Equity0.05
Current Ratio4.98
Quick Ratio4.81
Book Value/Sh0.2590 USD
Cash/Share0.6180 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Target (Mean)6.833 USD
Target Range4.000 USD – 9.000 USD
# Analysts6
Ownership
Shares Out.72.30M
Float67.44M
Insiders7.17%
Institutions38.88%
Short Interest
Short Ratio9.1d
Short % Float24.30%
Short % Out.19.92%
Shares Short14.40M
Short (prev mo.)14.09M
Technical
SMA 501.544 (-9.3%)
SMA 2001.505 (-7.0%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)1.34M
Avg Vol (10d)1.17M
Technical Indicators
RSI (14)44.4
MACD-0.0658
MACD Signal-0.0671
MACD Hist.+0.0012
BB Upper1.661 USD
BB Middle1.432 USD
BB Lower1.204 USD
BB Width31.94%
ATR (14)0.1224 USD
Vol Ratio (20d)0.33x